Analytically and Clinically Validated

The DISCERN™ Test

Skin is a window
to the brain

At SYNAPS Dx, we utilize a groundbreaking yet remarkably simple method for diagnosing Alzheimer’s disease. Our process requires only a crumb-sized skin sample, which can be easily collected during a quick and minimally invasive procedure.

The skin sample undergoes sophisticated biochemical analysis in our labs. By examining specific protein markers in the skin cells, DISCERN™ identifies the presence of Alzheimer's disease with over 95% accuracy. This advanced biomarker technology allows us to distinguish Alzheimer’s from other forms of dementia effectively.

the science

Learn More About Our Research

At SYNAPS Dx, we're dedicated to transparency in Alzheimer's diagnostics, offering an extensive suite of scientific resources. Our publications, whitepapers, and assay notes detail the robust science behind our DISCERN™ test.

Discover how our diagnostics are shaping Alzheimer’s care—visit our website to explore our scientific contributions.

Read our scientific papers

THE THREE BIOMARKERS

The three biomarkers

Morphometric Imaging

In a clinical trial with the Morphometric assay, patients with autopsy-confirmed AD could be accurately distinguished from patients with non-AD dementias and age-matched controls.

Sensitivity: 100%, Specificity 100%

MI Assay Science

PKCε Assay

In a clinical trial with the PKCε assay, patients with autopsy-confirmed AD could be accurately distinguished from patients with non-AD dementias and age-matched controls.

Sensitivity: 100%, Specificity 96%

PKCε Assay Science

AD-Index

In a clinical trial with the AD – Index assay, patients with autopsy-confirmed AD could be accurately distinguished from patients with non-AD dementias and age-matched controls.

Sensitivity 97%, Specificity 86%

AD-Index Assay Science

Learn More about discern™

Explore the Future of Alzheimer’s Diagnostics

Have questions or need assistance? We’re here to help!

Providing healthcare professionals with the necessary scientific data to identify Alzheimer’s Disease and distinguish it from other dementias - because being in doubt is simply not acceptable.

This test was developed, and its performance characteristics determined by NeuroDiagnostics Inc, dba Synaps Dx. It has not been cleared or approved by the U.S. Food and Drug Administration. NeuroDiagnostics, Inc. is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as an accredited laboratory to perform high complexity clinical testing. The test is intended for patients with dementia. Test results should be interpreted in conjunction with other laboratory and clinical data available to the clinician. All rights reserved.